Develops drugs for oncology, CNS disorders, and infectious diseases.
Dec 2024Revenue €797M/yrExpenses €939M/yr
Fell below break-even Apr 2023Cash runway ≈ 3.1 years from Dec 2024
Figures by year
When will Evotec be profitable again?
Its expenses passed its revenue in Apr 2023. In the 12 months to Dec 2024, revenue was €797M and expenses €939M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | €797M | €939M | −€143M |
| Dec 2023 | €781M | €829M | −€47.5M |
| Dec 2022 | €751M | €731M | €20.9M |
| Dec 2021 | €618M | €577M | €41.0M |
| Dec 2020 | €501M | €452M | €48.6M |
| Dec 2019 | €446M | €384M | €62.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.